DNDavid J. Nagel

David J. Nagel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David J. Nagel has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elastokines are potentially associated with a poor prognosis in idiopathic pulmonary fibrosis

    by David J Nagel, Takuma Okutani, Samia Lopa, Tj Mariani, Pj Sime, Rm Kottmann, Denise Hocking

    During the development of idiopathic pulmonary fibrosis (IPF), elastin is broken down and replaced with a stiffer substrate which interferes with normal breathing. This remodeling process releases elastin degradation products (EDPs), or elastokines, into the circulation and act as a surrogate for the degree of matrix turnover. We examined the association between elastokine concentrations with disease severity defined as abnormal lung function and transplant-free survival. Our objective was to determine if EDP concentrations are associated with clinically relevant markers of disease severity in IPF. Concentrations of elastokines were measured via enzyme linked immunosorbent assay (ELISA) from healthy volunteers and those with IPF. Samples were obtained from a single institution’s Interstitial Lung Disease (ILD) registry/biorepository (n = 81 with IPF and 24 healthy volunteers). We then used linear and logistic regression modeling, as well as Cox proportional hazard modeling, to assess the association between EDP concentrations at the time of diagnosis, lung function, and clinical outcomes. Patients with IPF were older, more likely to be male, had ever smoked, and had worse lung function compared to healthy volunteers (p value ≤ 0.02 for all parameters). Patients with IPF had higher concentrations of elastokines (p < 0.001), and among those with IPF, higher elastokine concentrations were associated with reduced forced vital capacity (FVC, p = 0.026), and decreased three-year transplant-free survival (p = 0.0005). These findings suggest that elastokines are biomarkers of matrix turnover and are associated with relevant clinical outcomes in patients with IPF.


  • Open Access

    Race-neutral spirometry reclassification in self-identified black and white patients

    by Xueya Cai, Felicia Canaday, Shan Gao, Eric Merrell, Patrick A. Donohue, Margaret Connolly, David J. Nagel, Sandhya Khurana, Steve N. Georas

    Recent consensus guidelines endorsed using a Global Lung Function Initiative (GLI Global) race-neutral approach to interpret spirometry. This study aims to examine how spirometry results using GLI Global reference equations correlate with patient health care utilization and outcomes in a real-world cohort of patients. Pulmonary function tests (PFTs) were analyzed via race-specific and GLI Global approaches, respectively, using a 2010–2020 retrospective cohort study of spirometry tests. An abnormally low result for either forced vital capacity (FVC) or forced expiratory volume in 1 s (FEV1) was defined as a z-score <−1.645. One year pulmonary medication prescription, outpatient visit, emergency department (ED) visit or hospitalization, as well as all-cause mortality were evaluated. Out of the total cohort of 6107 tests, 530 (9%) and 599 (10%) results were re-classified when switching from race-specific to race-neutral for FEV1 and FVC, respectively. Compared with patients whose lung function was consistently in the normal range (the control group), Black patients who were re-classified with an abnormally low FEV1 had higher health care utilization including pulmonary medication prescriptions, ED visits, and worse outcomes such as hospitalization. White subjects whose FEV1 was re-classified as normal also had worse outcomes including higher mortality than the consistently normal group. Similar results were obtained when analyzing FVC. We conclude that both Black and White subjects whose FEV1 and FVC were re-classified had worse outcomes compared to those who remained normal. Clinical context and judgment must be used when considering any lung function result near arbitrary thresholds of normal.

  • Open Access

    Acute Exacerbations of Interstitial Lung Disease: Evolving Perspectives on Diagnosis and Management

    by Carlo Arevalo, David J. Nagel

    SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.


  • Open Access

    Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation and Fibrosis; Potential Implications for Idiopathic Pulmonary Fibrosis

    by David J. Nagel, Ashley R. Rackow, Wei-Yao Ku, Tyler J. Bell, Patricia J. Sime, Robert Matthew Kottmann

    Idiopathic pulmonary fibrosis (IPF) is a disease characterized by irreversible lung scarring. The pathophysiology is not fully understood, but the working hypothesis postulates that a combination of epithelial injury and myofibroblast differentiation drives progressive pulmonary fibrosis. We previously demonstrated that a reduction in extracellular pH activates latent TGF-β1, and that TGF-β1 then drives its own activation, creating a feed-forward mechanism that propagates myofibroblast differentiation. Given the important roles of extracellular pH in the progression of pulmonary fibrosis, we sought to identify whether pH mediates other cellular phenotypes independent of TGF-β1. Proton-sensing G-protein coupled receptors are activated by acidic environments, but their role in fibrosis has not been studied. Here, we report that the Ovarian Cancer G-Protein Coupled Receptor1 (OGR1 or GPR68) has dual roles in both promoting and mitigating pulmonary fibrosis. We demonstrate that OGR1 protein expression is significantly reduced in lung tissue from patients with IPF and that TGF-β1 decreases OGR1 expression. In fibroblasts, OGR1 inhibits myofibroblast differentiation and does not contribute to inflammation. However, in epithelial cells, OGR1 promotes epithelial to mesenchymal transition (EMT) and inflammation. We then demonstrate that sub-cellular localization and alternative signaling pathways may be responsible for the differential effect of OGR1 in each cell type. Our results suggest that strategies to selectively target OGR1 expression may represent a novel therapeutic strategy for pulmonary fibrosis.


  • Open Access

    The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops

    by Ashley R. Rackow, David J. Nagel, Claire McCarthy, Jennifer Judge, Shannon Lacy, Margaret A.T. Freeberg, Thomas H. Thatcher, R. Matthew Kottmann, Patricia J. Sime

    Pulmonary fibrosis is a devastating, progressive disease and carries a prognosis worse than most cancers. Despite ongoing research, the mechanisms that underlie disease pathogenesis remain only partially understood. However, the self-perpetuating nature of pulmonary fibrosis has led several researchers to propose the existence of pathological signalling loops. According to this hypothesis, the normal wound-healing process becomes corrupted and results in the progressive accumulation of scar tissue in the lung. In addition, several negative regulators of pulmonary fibrosis are downregulated and, therefore, are no longer capable of inhibiting these feed-forward loops. The combination of pathological signalling loops and loss of a checks and balances system ultimately culminates in a process of unregulated scar formation. This review details specific signalling pathways demonstrated to play a role in the pathogenesis of pulmonary fibrosis. The evidence of detrimental signalling loops is elucidated with regard to epithelial cell injury, cellular senescence and the activation of developmental and ageing pathways. We demonstrate where these loops intersect each other, as well as common mediators that may drive these responses and how the loss of pro-resolving mediators may contribute to the propagation of disease. By focusing on the overlapping signalling mediators among the many pro-fibrotic pathways, it is our hope that the pulmonary fibrosis community will be better equipped to design future trials that incorporate the redundant nature of these pathways as we move towards finding a cure for this unrelenting disease.


  • Open Access

    Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol

    by Jennifer L Judge, David J Nagel, Kristina M Owens, Ashley Rackow, Richard P Phipps, Patricia J Sime, R M Kottmann

    Pulmonary fibrosis is a chronic and irreversible scarring disease in the lung with poor prognosis. Few therapies are available; therefore it is critical to identify new therapeutic targets. Our lab has previously identified the enzyme lactate dehydrogenase-A (LDHA) as a potential therapeutic target in pulmonary fibrosis. We found increases in LDHA protein and its metabolic product, lactate, in patients with idiopathic pulmonary fibrosis (IPF). Importantly, we described lactate as a novel pro-fibrotic mediator by acidifying the extracellular space, and activating latent transforming growth factor beta (TGF-β1) in a pH-dependent manner. We propose a pro-fibrotic feed-forward loop by which LDHA produces lactate, lactate decreases pH in the extracellular space and activates TGF-β1 which can further perpetuate fibrotic signaling. Our previous work also demonstrates that the LDHA inhibitor gossypol inhibits TGF-β1-induced myofibroblast differentiation and collagen production in vitro. Here, we employed a mouse model of bleomycin-induced pulmonary fibrosis to test whether gossypol inhibits pulmonary fibrosis in vivo. We found that gossypol dose-dependently inhibits bleomycin-induced collagen accumulation and TGF-β1 activation in mouse lungs when treatment is started on the same day as bleomycin administration. Importantly, gossypol was also effective at treating collagen accumulation when delayed 7 days following bleomycin. Our results demonstrate that inhibition of LDHA with the inhibitor gossypol is effective at both preventing and treating bleomycin-induced pulmonary fibrosis, and suggests that LDHA may be a potential therapeutic target for pulmonary fibrosis.